The Value Of Neoadjuvant Chemotherapy In The Treatment Of Breast Cancer

Objective: To investigate the vale of the neoadjuvant chemotherapy in the treatment of breast cancer.Methods: We gathered 207 primary breast cancer patients diagnosised by core needle biopsy before the treatment, who accepted neoadjuvant chemotherapy(NAC), using TEC,CEF or cisplatin-based scheme, for 2~5 cycles, after that all be treated by surgery, from 2006.1 to 2009.11. Detected the ER,PR,HER-2 and p53 in both the biopsy and the surgery specimens by immunohistochemistry.Results: Before and after NAC, the ER,PR,HER-2,p53,axillary lymph node positive rate were 56.8% and 48.1%, 39.5% and 33.3%, 45.7% and 43.2%, 38.3% and 33.3%, 56.0% and 78.3%, respectively. The total effective rate of ER,PR,p53 positive and negative breast cancer were 45.4% and 61.6%, 43.3% and 60.7%, 49.2% and 54.8%,respectively;the total effective rate of HER-2 over-expression and non-over-expression, the TEC scheme and the CEF scheme, preoperative use of 2 cycles and the use of more than 2 cycles groups, were 51.6 % and 53.4%, 41.0% and 57.1%, 48.3% and 64.5%, respectively; the total effective rate of aged≤40 and >40 years groups,the non-menopausal and menopausal groups,TNBC and non-TNBC groups, were 44.4% and 55.0%,47.4% and 57.5%,69.2% and 50.8%,respectively.Conclusion: Neoadjuvant chemotherapy couldn't change the expression of ER, PR, HER-2, p53, but it could reduce the rate of axillary lymph nodes significatively; NAC was significatively more effective in ER, PR-negative breast cancer, however, HER-2 over-expression and p53-negative breast cancer had better effection, with no statistical difference; TEC scheme was better than CEF scheme , and >2 cycles of treatment was better than 2 cycles, with statistical difference; aged >40 years of age and postmenopausal breast cancer had higher efficiency; NAC efficiency of the TNBC group was higher than non-TNBC group.